title: [Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
abstract: A 60-year-old man was examined at a local clinic for difficulty in urinating, and was diagnosed with prostatic hypertrophy. He was referred to our department because his prostate-specific antigen (PSA) level was elevated (276 ng/ml). His Gleason score was 4＋3, there was one bone metastasis in the left ileac bone, and multiple lung metastases were present. The patient was accordingly diagnosed with stage D2 prostate cancer. Lutenizing hormone-releasing hormone (LH-RH) analogue treatment was initiated in April 1999, and 9 months later the PSA level had decreased to 4.3 ng/ml. Six years and 9 months after the start of hormone therapy, the cancer had developed into castration-resistant prostate cancer and the PSA level had risen to 43.8 ng/ml. Paclitaxel-carboplatin therapy was therefore initiated. Eight months after the start of chemotherapy, the PSA level had decreased to 25.9 ng/ml, but 6 years and 1 month later it had risen to 925 ng/ml, and the chemotherapy was discontinued. Docetaxel-predonine therapy was initiated in March 2012. Three months after the start of chemotherapy, the PSA level had decreased to 3.1 ng/ml, and the bone metastasis was reduced.
authors.affiliation: The Department of Urology, Faculty of Medical Science, University of Fukui.
authors.forename: Naoya
authors.initials: N
authors.lastname: Kusukawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Ishida
authors.forename: Kazuya
authors.initials: K
authors.lastname: Tanase
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ito
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Aoki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ooyama
authors.forename: Hironobu
authors.initials: H
authors.lastname: Akino
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokoyama
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000494:pharmacology; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D011239:Prednisolone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D011239:Prednisolone; D016190:Carboplatin; D017239:Paclitaxel